No Detail Found!

Comparative Safety and Pharmacokinetic Variability of Direct Oral Anticoagulants in Patients with Chronic Kidney Disease: A Systematic Review

Author(s)
Moamen Abdelfadil Ismail King Abdulaziz Specialist Hospital, Saudi Arabia
Aisha Awaji Hakami Pharmacy Department, Saudi Arabia
Batool A. Almenayan Pharmacy Department, University of Hafr Albatin, Saudi Arabia
Mohammed A. Asiri Clinical Pharmacy, England. PharmD, Saudi Arabia
Omar Abdulaziz Aljawi IPPR Graduate, Saudi Arabia
Rasha Ahmed Alzahrani King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia
Lujain Mneef Salm Almalki College of Pharmacy, Taif University, Taif 21944, Saudi Arabia
Abstract
Background: Anticoagulation therapy becomes more challenging in patients with chronic kidney disease (CKD) due to the increased risk of thromboembolic and bleeding events. While DOACs have several benefits over more conventional treatments, there is still much we don't know about their pharmacokinetics and safety in CKD. Objective: In order to conduct a comprehensive analysis of the relative safety and pharmacokinetic variability of DOACs in CKD patients. Methods: In accordance with PRISMA 2020 standards, a systematic review was car r ied out. Up to December 2025, electronic databases were combed through. We considered studies that looked at the pharmacokinetics, bleeding r isk, and thromboembolic outcomes of DOACs in CKD. Eleven research, compr ising pharmacokinetic studies, randomized tr ials, and cohor t studies, fulfilled the inclusion cr iter ia. Results: Significant pharmacokinetic variability was observed across DOACs. Dabigatran showed high renal dependence and increased accumulation risk in advanced CKD, while apixaban demonstrated stable pharmacokinetics and minimal dialyzability. Rivaroxaban exhibited intermediate characteristics. In hemodialysis populations, dabigatran and rivaroxaban were related to higher rates of bleeding, but apixaban consistently linked with a decreased major bleeding risk than warfarin. Evidence regarding thromboembolic outcomes was mixed, with some studies showing no significant benefit of anticoagulation in dialysis patients. Conclusion: DOACs demonstrate variable safety and pharmacokinetic profiles in CKD. Apixaban appears to offer the most favorable balance between efficacy and safety, while dabigatran should be avoided in advanced CKD. Individualized treatment decisions are essential, and to determine the best anticoagulation therapies for this group, further randomized trials are required.
Publication Details
Page(s) 222-229
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: 5, Year: 2026

Request the full text from PASTIC

Keywords
Bleeding Risk, direct oral anticoagulants, Pharmacokinetics, Chronic Kidney Disease, Apixaban, Hemodialysis, Anticoagulation, Dabigatran, Thromboembolism, Rivaroxaban
References
Su X. .2022 .Comparative efficacy and safety of oral anticoagulants for venous thromboembolism in patients with different renal functions: A systematic review, pairwise and network meta-analysis. ” BMJ Open, 12(2) : 048619.
Bonde Nissen,A. Nissen .2018 .Use of oral anticoagulation and association to outcomes in atrial fibrillation patients who develop chronic kidney disease. ” European Heart Journal, 1(Suppl) : .
Agnelli G. . .Oral apixaban for the treatment of acute venous thromboembolism. ” New England Journal of Medicine, 369(2013) : 799-808.
Büller H.R. .2013 .Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. ” New England Journal of Medicine, 369(15) : 1406-1415.
Elshafei M.N. . .Comparative effectiveness and safety of direct oral anticoagulants in low body weight patients with atrial fibrillation: A systematic review and meta-analysis,” Cardiovascular Drugs and Therapy. , 39(2025) : 643-660.
Tham D. .2024 .Safety and efficacy of direct oral anticoagulants in chronic kidney disease: A meta-analysis. ” Research and Practice in Thrombosis and Haemostasis, 102584(7) : .
Martinez Calderon,E. Calderon . .Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease: A systematic review and meta-analysis. ” Journal of Nephrology, 38(2025) : 111-126.
Grandone E. . .Position paper on the safety and efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. ” Journal of Nephrology, 34(2021) : 31-38.
Hijazi Z. . .Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: A RE-LY trial analysis. ” Circulation, 129(2014) : 961-970.
Montomoli M. .2022 .Oral anticoagulation in patients with chronic kidney disease and non-valvular atrial fibrillation: The FAERC study. ” Healthcare, 2566(12) : .
Lee K.H. . .Comparison of non-vitamin K antagonist oral anticoagulants and warfarin on clinical outcomes in atrial fibrillation patients with renal dysfunction,” Europace. , 2(2015) : ii69-ii75.
Jun M. . .Kidney function and the comparative effectiveness and safety of direct oral anticoagulants vs. warfarin in adults with atrial fibrillation: A multicenter observational study. ” European Heart Journal - Quality of Care and Clinical Outcomes, 9(2023) : 621-631.
Elfar S. .2022 .Direct oral anticoagulants vs. warfarin in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis,” Frontiers in Cardiovascular Medicine. , 847286 : .
Thompson L.E. . .Personalizing direct oral anticoagulant therapy for a diverse population: Role of race, kidney function, drug interactions, and pharmacogenetics. ” Clinical Pharmacology and Therapeutics, 113(2023) : 585-599.
Elenjickal E.J. . .Anticoagulation in patients with chronic kidney disease. American Journal of Nephrology, 55(2024) : 146-164.
Khadzhynov D. . .Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. ” Thrombosis and Haemostasis, 109(2013) : 596-605.
De Vriese A.S. .2015 .Dose-finding study of rivaroxaban in hemodialysis patients. American Journal of Kidney Diseases, 01(2015) : 91-98.
Mavrakanas T.A. . .Apixaban pharmacokinetics at steady state in hemodialysis patients. ” Journal of the American Society of Nephrology, 28(2017) : 2241-2248.
Chan K.E. .2015 .Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. ” Circulation, 131(11) : 972-979.
Siontis K.C. .2018 .Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. , 138(15) : 1519-1529.
Sarratt S.C.,Nesbit R.,Moye R. . .Safety outcomes of apixaban compared with warfarin in patients with end-stage renal disease. ” Annals of Pharmacotherapy, 51(2017) : 445-450.
Stanifer J.W. .2020 .Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. ” Circulation, 141(17) : 1384-1392.
Miao B. . .Rivaroxaban versus apixaban in nonvalvular atrial fibrillation patients with end-stage renal disease. European Journal of Haematology, 104(2020) : 328-335.
Mavrakanas T.A. . .Apixaban versus no anticoagulation in patients undergoing long-term dialysis with incident atrial fibrillation,”. Clinical Journal of the American Society of Nephrology, 15(2020) : 1146-1154.
Yang F. .2017 .Warfarin utilization and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. ” Heart, 103(11) : 818-826.
De Vriese A.S. . .Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: The Valkyrie study. ” Journal of the American Society of Nephrology, 31(2020) : 186-196.
Coleman C.I. . .Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis. American Journal of Medicine, 132(2019) : 1078-1083.
0

Citations

0

Downloads

21

Views